Biomarker & Intervention Discovery
Prostate Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs837.7KWHO GHE 2021 · all ages
Global DALYs7.74MWHO GHE 2021 · worldwide
US mortality37.3K deaths/yrWHO GHE 2021
Global mortality393.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$314MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionLow-grade (Gleason 6/Grade Group 1): active surveillance appropriate in 40-50% — many will never need treatment…
Best-intervention remissionLocalised: surgery (radical prostatectomy) or radiotherapy — 90-95% disease-specific survival at 10 years; mCSPC:…
Gap sizeLarge — active surveillance underused in low-risk disease (overtreatment); ADT monotherapy still used where…
Primary barrierpractice
Full remission profile →
Remission & chronicity
Spontaneous remission
Low-grade (Gleason 6/Grade Group 1): active surveillance appropriate in 40-50% — many will never need treatment; high-grade: lethal without treatment within 5-10 years
Best-intervention remission
Localised: surgery (radical prostatectomy) or radiotherapy — 90-95% disease-specific survival at 10 years; mCSPC: darolutamide + docetaxel + ADT (ARASENS): 32% OS improvement; enzalutamide/abiraterone + ADT as standard 2019-2021; PARP inhibitors for BRCA-mutant: olaparib — 34% OS benefit (PROfound)
Gap size
Large — active surveillance underused in low-risk disease (overtreatment); ADT monotherapy still used where combination therapy is standard
Active surveillance in low-risk PCa is guideline-endorsed but only 50-60% of eligible patients are managed this way (radical treatment used unnecessarily with significant sexual/urinary side effects); intensified ADT combinations are standard of care for mHSPC but ADT monotherapy still prescribed
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Prostate Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."